Scarica l'app Stockscreener
7.15
1.42%
0.10
Zevra Therapeutics Inc Borsa (ZVRA) Ultime notizie
Zevra Therapeutics (ZVRA) Reveals Key Insights into Niemann-Pick Type C Treatment | ZVRA Stock News - GuruFocus
Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism | ZVRA Stock News - GuruFocus
Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism - GlobeNewswire
Breakthrough Study Uncovers MIPLYFFA's Mechanism for Treating Fatal Genetic Disease NPC - Stock Titan
Institutional investors may overlook Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) recent US$44m market cap drop as long-term gains remain positive - simplywall.st
Zevra Announces Closing Of Sale Of Rare Pediatric Disease Priority Review Voucher - MarketScreener
Zevra Therapeutics Nets $150 Million From US FDA Voucher Sale, Increases Cash Reserves - marketscreener.com
Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million - GlobeNewswire
$150M FDA Voucher Sale Transforms Zevra's Financial Position: Rare Disease Success Story - Stock Titan
Earnings Preview: Zevra Therapeutics (ZVRA) Q2 Earnings Expected to Decline - MSN
(ZVRA) Technical Data - news.stocktradersdaily.com
Zevra Therapeutics: Mixed Feelings On Miplyffa Approval (NASDAQ:ZVRA) - Seeking Alpha
Zevra therapeutics director Corey Watton buys $2,351 in stock By Investing.com - Investing.com Australia
Zevra therapeutics director Corey Watton buys $2,351 in stock - Investing.com India
Zevra Therapeutics Asks Shareholders to Reject Director Nominees by Activist Investor - MarketScreener
Zevra Therapeutics Files Preliminary Proxy - The Manila Times
Proxy Fight Erupts at Zevra: Former CEO Challenges $150M Cash-Rich Biotech - Stock Titan
Trend Tracker for (ZVRA) - news.stocktradersdaily.com
John Bode Bought 33% More Shares In Zevra Therapeutics - simplywall.st
Zevra Therapeutics Independent Director Acquires 33% More Stock - Yahoo Finance
Insider Buying: John Bode Acquires Additional Shares of Zevra Th - GuruFocus
Zevra therapeutics director Bode acquires $79,624 in stock By Investing.com - Investing.com Canada
Zevra therapeutics director Bode acquires $79,624 in stock - Investing.com
ZEVRA THERAPEUTICS Director John B Bode Acquires 10,000 Shares - TradingView
Woodline Partners LP's Strategic Acquisition of Zevra Therapeuti - GuruFocus.com
Zevra Therapeutics’ SWOT analysis: stock poised for growth amid rare disease focus - Investing.com Australia
Zevra Therapeutics’ SWOT analysis: stock poised for growth amid rare disease focus By Investing.com - Investing.com South Africa
HC Wainwright Predicts Lower Earnings for Zevra Therapeutics - Defense World
(ZVRA) On The My Stocks Page - news.stocktradersdaily.com
Guggenheim Forecasts Strong Price Appreciation for Zevra Therapeutics (NASDAQ:ZVRA) Stock - Defense World
Zevra Therapeutics (NASDAQ:ZVRA) Earns Overweight Rating from Cantor Fitzgerald - Defense World
Roth Capital Predicts Weaker Earnings for Zevra Therapeutics - Defense World
Zevra Therapeutics (ZVRA) Reports Q4 Loss, Tops Revenue Estimates - MSN
Canaccord raises Zevra Therapeutics target to $25; Keeps Buy rating By Investing.com - Investing.com Australia
Zevra Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Benzinga
Optimistic Buy Rating for Zevra Therapeutics Driven by Miplyffa Launch and Strategic Financial Moves - TipRanks
Canaccord raises Zevra Therapeutics target to $25; Keeps Buy rating - Investing.com India
Zevra Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Zevra Therapeutics’ Earnings Call Highlights Success and Growth - TipRanks
Sector Update: Health Care -March 12, 2025 at 01:43 pm EDT - Marketscreener.com
Cantor Fitzgerald maintains $25 target on Zevra Therapeutics stock - Investing.com
Zevra Therapeutics stock target raised to $18 at JMP - Investing.com India
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q4 2024 Earnings Call Transcript - Insider Monkey
Cantor Fitzgerald maintains $25 target on Zevra Therapeutics stock By Investing.com - Investing.com South Africa
Zevra Therapeutics stock target raised to $18 at JMP By Investing.com - Investing.com South Africa
Zevra Therapeutics Inc (ZVRA) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ... - Yahoo Finance
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Recommendation of “Buy” by Analysts - Defense World
Earnings call transcript: Zevra Therapeutics Q4 2024 reports wider losses By Investing.com - Investing.com Australia
Zevra Therapeutics Inc (ZVRA) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic Expansion Plans - GuruFocus.com
Zevra Therapeutics: Strong Financial Performance and Strategic Growth Justify Buy Rating - TipRanks
Zevra Therapeutics: Q4 Earnings Snapshot - The Washington Post
Zevra Therapeutics Reports 2024 Financial Results and Strategic Progress - TipRanks
2.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):